Lupin announced that the Drug Controller General of India approved the company’s Vilfuro-G vilanterol / fluticasone furoate / glycopyrronium bromide dry powder inhaler for the treatment of COPD, and the company has launched the DPI in India. Earlier this year, Lupin announced the launch of its Difizma indacaterol / glycopyrronium / mometasone DPI in India for the treatment of inadequately controlled asthma.
Lupin Managing Director Nilesh Gupta commented, “We are delighted to introduce Vilfuro-G, a testament to our commitment to our patients and our focus on innovation. This milestone reinforces our resolve to expanding our respiratory portfolio, providing COPD patients with access to healthcare solutions, and transforming lives.”
President of India Region Formulations Rajeev Sibal added, “As the global prevalence of COPD continues to surge, India bears a significant 18% of this disease burden. With our extensive respiratory portfolio and the approval of Vilfuro-G, we take immense pride in offering healthcare professionals and patients with innovative treatment solutions.”
Read the Lupin press release.
